HC Wainwright Has Positive Outlook for INKT FY2028 Earnings

MiNK Therapeutics, Inc. (NASDAQ:INKT) – Research analysts at HC Wainwright upped their FY2028 earnings per share (EPS) estimates for shares of MiNK Therapeutics in a report issued on Thursday, November 14th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of $0.24 per share for the year, up from their previous estimate of $0.16. HC Wainwright currently has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($0.33) per share.

Separately, Robert W. Baird dropped their price target on shares of MiNK Therapeutics from $8.00 to $4.00 and set an “outperform” rating on the stock in a research note on Friday.

MiNK Therapeutics Stock Performance

Shares of INKT opened at $0.70 on Monday. The firm has a market cap of $27.48 million, a PE ratio of -1.78 and a beta of 0.05. The firm’s 50 day moving average price is $0.73 and its 200 day moving average price is $0.85. MiNK Therapeutics has a twelve month low of $0.57 and a twelve month high of $1.90.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in MiNK Therapeutics stock. Renaissance Technologies LLC boosted its stake in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 21.5% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 127,841 shares of the company’s stock after purchasing an additional 22,613 shares during the quarter. Renaissance Technologies LLC owned about 0.37% of MiNK Therapeutics worth $121,000 at the end of the most recent quarter. 2.87% of the stock is currently owned by institutional investors and hedge funds.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.